Please use this identifier to cite or link to this item: https://www.arca.fiocruz.br/handle/icict/11778
Title: Considerations on clinical trials of leprosy treatment: need of novel drug combinations
Authors: Illarramendi, Ximena
Oliveira, Maria Leide Wand del Rey de
Sales, Ana Maria
Nery, José Augusto da Costa
Sarno, Euzenir Nunes
Affilliation: Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Hanseníase. Rio de Janeiro, RJ, Brasil.
Universidade Federal do Rio de Janeiro. Departamento de Dermatologia. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Hanseníase. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Hanseníase. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Hanseníase. Rio de Janeiro, RJ, Brasil.
Abstract: Considering that after 30 years of using multidrug therapy (MDT), leprosy eradication has still not been achieved, leprosy treatment must remain on the drug discovery agenda. Due to the complexities inherent in leprosy disease and the many methodological issues involved in clinical trials, the task of translating the bench findings into clinical practice has been arduous. While the effectiveness of reducing the currently recommended MDT remains controversial, a number of highly bactericidal antibiotics and immune-modulatory drugs have emerged as prospective candidates to improve patient adherence and quality of life, reduce adverse effects and prevent resistance. To replace the standard WHO-MDT, the new combination must be the shortest, simplest and, consequently, most affordable treatment possible.
Keywords: Clinical trial
Drug combination
Leprosy
Multidrug therapy
Relapse
Resistance
Surrogate end point
Treatment
keywords: Resistência
DeCS: Hanseníase
Ensaio Clínico
Múltiplos Medicamentos
Recidiva
Issue Date: 2013
Publisher: Future Science Group
Citation: ILLARRAMENDI, Ximena; et al. Considerations on clinical trials of leprosy treatment: need of novel drug combinations. Clin. Invest., v.3, n.7, p.617-635, 2013.
DOI: 10.4155/CLI.13.52
Copyright: open access
Appears in Collections:IOC - Artigos de Periódicos

Files in This Item:
File Description SizeFormat 
euzenir_sarno_etal_IOC_2013.pdf1.75 MBAdobe PDFView/Open



FacebookTwitterDeliciousLinkedInGoogle BookmarksBibTex Format mendeley Endnote DiggMySpace

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.